YOLFTbeta
Sunshine Biopharma Inc

Sunshine Biopharma Inc

SBFM · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

2.70USD-0.14 (-4.93%)

Price History

Full chart

Market Stats

Previous Close2.84
Open2.72
Day Range2.70 – 2.78
52-Week Range0.778 – 24.30
Volume27.45K
Market Cap3.27M
P/E (TTM)0.00
Forward P/E0.00
EPS-9.16
Dividend Yield0.00%
Beta1.32
50-Day Avg1.23
200-Day Avg7.14

About

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Steve N. Slilaty Ph.D.
  • Employees50
  • Headquarters333 Las Olas Way, Fort Lauderdale, FL, United States, 33301, USA
  • Websitehttps://sunshinebiopharma.com

Leadership

  • Dr. Steve N. Slilaty Ph.D.Chairman, President & CEO · b. 1952
  • Mr. Camille SebaalyCFO, Secretary & Director · b. 1959
  • Mr. Michel RoyChief Commercial Officer · b. 1968
  • Mr. Malek ChamounChief Development Officer · b. 1985
  • Mr. Robert G. FerreiraPresident of Sunshine Bio Investments Inc · b. 1962

Financials

Income Statement

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue------001.71K00447.20K21.12K71.41K228.43K4.35M24.09M34.87M36.31M
Growth (%)----------100.00%---95.28%+238.10%+219.88%+1802.41%+454.42%+44.75%+4.11%
Cost of Revenue-----250.00K475.00K263.33K384.58K60.73K6.63K391.08K11.05K25.85K117.83K2.65M15.75M24.20M24.38M
Gross Profit------250.00K-475.00K-263.33K1.71K-60.73K-6.63K56.12K10.07K45.56K110.60K1.70M8.34M10.67M11.92M
Gross Margin--------100.00%--12.55%47.68%63.80%48.42%39.04%34.61%30.60%32.84%
Operating Expense-----456.68K1.46M1.49M781.99K932.38K850.56K1.22M651.71K622.44K2.55M10.37M13.12M16.48M16.40M
Operating Income-13.12K-26.08K-15.65K-537.38K-556.20K-706.68K-1.94M-1.76M-780.28K-993.11K-857.19K-1.17M-641.64K-576.87K-2.44M-8.67M-4.79M-5.81M-4.48M
Operating Margin---------45683.67%---260.85%-3037.91%-807.83%-1068.24%-199.60%-19.86%-16.67%-12.34%
EBITDA-13.12K-26.08K-15.65K-537.38K-556.20K-706.68K-1.94M-1.76M-1.34M-932.38K-928.78K-1.99M-948.38K-2.60M-12.09M-26.45M-3.82M-5.14M-5.62M
EBITDA Margin---------78538.99%---444.75%-4490.22%-3643.64%-5294.88%-608.58%-15.87%-14.73%-15.48%
Net Income-13.12K-31.11K-25.02K-537.38K-556.20K-707.95K-2.49M-1.93M-1.65M-3.50M-1.04M-2.16M-1.66M-2.78M-12.44M-26.74M-4.51M-5.13M-5.98M
Net Income Margin---------96774.47%---482.15%-7860.85%-3898.74%-5444.41%-615.44%-18.70%-14.72%-16.46%
R&D----142.65K1.83K137.40K327.00K8.66K32.79K012.80K15.20K1.73K672.21K811.86K1.86M933.90K604.31K
R&D as % of Total Revenue--------506.85%--2.86%71.99%2.42%294.28%18.68%7.70%2.68%1.66%
Interest Expense13.12K5.03K9.36K-556.20K1.27K6.46K179.10K307.21K34.73K104.83K159.42K115.90K168.10K328.82K39.41K137.31K8.77K0
Interest Expense % of Total Revenue--------17986.59%--35.65%548.75%235.41%143.95%0.91%0.57%0.03%0.00%

Balance Sheet

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.89K5.03K112.12K207.62K106.44K134.79K31.24K143.42K673.26K64.40K257.49K1.15M98.14K1.05M2.20M29.55M27.35M30.56M30.08M
Total Liabilities1.50K22.74K14.31K11.40K3.43K64.37K38.95K531.00K1.27M274.10K830.85K1.20M833.53K2.00M1.99M7.92M6.14M7.06M7.04M
Total Equity13.39K-17.71K97.80K196.22K103.00K70.43K-7.71K-387.58K-597.04K-209.70K-573.36K-55.75K-735.38K-954.84K211.66K21.63M21.21M23.50M23.04M
Cash14.89K4.36K112.12K162.39K60.69K132.64K31.24K143.42K50.80K57.45K107.53K115.22K40.50K989.89K2.05M21.83M16.29M9.69M9.12M
Total Debt-17.00K31.00K--62.50K12.50K480.12K1.14M236.97K802.32K952.60K715.57K1.91M1.90M765.26K657.71K952.48K812.42K
Net Debt-14.89K12.64K-81.12K-162.39K-60.69K-70.14K-18.74K336.70K1.09M179.52K694.79K837.39K675.07K923.23K-145.17K-21.06M-15.63M-8.73M-8.31M

Cash Flow

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.12K-23.03K-10.22K-348.32K-297.30K-393.05K-564.40K-538.60K-867.64K-314.18K-543.52K-512.81K-495.80K-657.30K-1.83M-5.25M-8.78M-12.53M-5.33M
Investing Cash Flow-------623.60K-623.60K-623.30K-3.44K-84.01K-13.91K-15.28K-1.19K-14.62M-14.62M-656.15K-2.32M-836.31K
Financing Cash Flow18.02K12.50K6.50K398.60K195.60K465.00K463.00K650.78K1.40M324.62K670.71K527.64K442.25K1.61M2.90M39.47M3.43M9.29M4.75M
Capital Expenditure0000004.79K4.79K623.60K3.44K3.72K18.85K8601.19K2305.00K788.10K2.32M174.49K
Free Cash Flow-3.12K-23.03K-10.22K-348.32K-297.30K-393.05K-564.40K-538.60K-1.49M-317.62K-547.24K-531.66K-496.66K-658.49K-1.83M-5.55M-9.56M-14.85M-5.51M
Dividends Paid-----------000-----
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%171.87%101.09%100.68%103.68%100.17%100.18%100.00%105.81%108.98%118.52%103.27%
Dividend Paid to FCF-----------0.00%0.00%0.00%-----

Earnings

Report DateMar 31, 2010Jun 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017May 12, 2017Aug 11, 2017Nov 15, 2017Mar 31, 2018Apr 2, 2018Aug 17, 2018Nov 16, 2018Mar 31, 2019Apr 12, 2019Aug 15, 2019Nov 13, 2019Mar 31, 2020May 1, 2020Aug 19, 2020Nov 11, 2020Mar 30, 2021May 11, 2021Aug 9, 2021Nov 9, 2021Mar 21, 2022May 6, 2022Aug 4, 2022Nov 7, 2022Dec 31, 2022May 11, 2023Aug 10, 2023Nov 13, 2023Mar 28, 2024May 20, 2024Aug 16, 2024Nov 5, 2024Dec 31, 2024May 15, 2025Aug 12, 2025Nov 13, 2025Feb 25, 2026May 13, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate------------------------------------------------------1600.00-1200.00-3.00-208.00-6.00-5350.000.010.07-1.10-1.30-0.12-1.60-1.20-
EPS Actual-456624.23-1000000.00-4.97-0.64-0.21-1.52-4.75-0.32-0.85-3.00-1.47-10.67-1.08-1.25-4.88-3.28-4.68-1.66-2.18-1.82-1.73-0.62-1.62-0.57-0.73-1.09-1.18-0.10-0.23-0.07-0.09-0.11-0.26-0.36-0.07-0.05-0.03-0.04-0.01-0.00-0.01-0.01-0.00-0.01-0.01-0.01-0.010.26-0.23-0.03-0.08-2082.06-1.05-400.00-800.00-5.00-400.00-1988.00-9.40--0.44-3.90-1.90-0.46-2.50-1.15-
Surprise-----------------------------------------------------75.00%33.33%-66.67%-92.31%-33033.33%99.82%--728.57%-254.55%-46.15%-283.33%-56.25%4.17%-
Timing-------------------------------------------------After-hours--Pre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours--After-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap3.27M
Enterprise Value-9.54M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales0.09
Price / Book0.13
EPS-9.16
Book Value11.52
Revenue (TTM)35.35M
Gross Profit (TTM)10.71M
EBITDA-4.85M
Profit Margin-16.50%
Operating Margin-17.41%
Return on Equity-21.92%
Return on Assets-9.91%
Shares Outstanding3.88M
Shares Float3.81M
Beta1.32
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 56.00
  • Strong Buy
    1

Ownership Breakdown

Institutions
7.13%
Insiders
1.77%
Retail / Other
91.10%

Top Institutional Holders

  • TWO SIGMA SECURITIES, LLC
    23.48K0.01%
  • XTX Topco Ltd
    21.46K0.01%
  • Morgan Stanley - Brokerage Accounts
    14.63K0.01%
  • SBI Securities Co Ltd
    1.83K0.00%
  • UBS Group AG
    1.10K0.00%
  • NATIONAL BANK OF CANADA /FI/
    50.00%
  • Advisor Group Holdings, Inc.
    20.00%
  • TD Waterhouse Canada Inc
    10.00%
  • Commonwealth Equity Services, LLC
    00.00%
  • Strive Financial Group ,LLC
    00.00%
  • Citadel Advisors Llc
    00.00%
  • Virtu Financial LLC
    00.00%
  • CoreCap Advisors, LLC
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Stewardship Partners US Multifactor
    4.19K0.20%
  • Stewardship Partners Global Multifactor
    1.69K0.08%
  • Stewardship Partners Glb Multi Tax-Eff
    6780.03%

Stock Splits

  • Oct 26, 20261:20
  • Jun 1, 20261:10
  • Aug 8, 20241:20
  • Apr 17, 20241:100